FDA Grants Orphan Drug Status to Eledon's Tegoprubart for Liver Transplant Rejection
Summary
Eledon Pharmaceuticals announced that its lead investigational product, tegoprubart, has received Orphan Drug Designation (ODD) from the FDA for the prevention of allograft rejection in liver transplantation. This designation is a positive regulatory milestone, providing incentives such as tax credits, fee waivers, and potential 7-year market exclusivity upon approval. For a clinical-stage biotech like Eledon, this expands the potential market for tegoprubart and de-risks its development pathway in a new, significant indication. The company plans to evaluate tegoprubart's potential in liver transplantation through an anticipated investigator-sponsored trial initiating later this year.
At the time of this announcement, ELDN was trading at $3.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $217.7M. The 52-week trading range was $1.35 to $4.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.